Vigonvita Life Sciences Co., Ltd. (2630.HK)
HKSE · HKD · Healthcare · Drug Manufacturers - General
HK$76.80 (-2.78%) as of
Key statistics
- Market cap
- 12.87B
- EPS (TTM)
- -2.300
- Dividend yield
- 0.00%
- 52-week range
- 51.000 – 134.900
- Revenue (TTM)
- 217.26M
- Profit margin
- -140.28%
- Volume
- 88.40k
About Vigonvita Life Sciences Co., Ltd.
Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116, a RNA-dependent RNA polymerase inhibitor completed a Phase II clinical trial for the treatment of respiratory syncytial virus infection, as well as COVID-19 infections; TPN102, a novel antiepileptic drug, which is in Phase I clinical trial for the treatment of epilepsy; VV119, a multi-target serotonin-dopamine activity modulator, which is in Phase I clinical trial for the treatment of psychiatric disorders and schizophrenia; VV261, a novel nucleoside prodrug, which is in Phase I clinical trial for chikungunya, coronaviruses, influenza, and arena virus. In addition, it develops VV913, a novel investigational drug candidate for premature ejaculation; VV147 for the treatment of major depressive disorder; and VV207 for the treatment of adenovirus infection. The company was incorporated in 2013 and is headquartered in Suzhou, China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- Suzhou, China
- Employees
- 351
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.